Palisade Bio Q2 FY26 net loss widens 280% to $10.57 million

• Palisade Bio posted a net loss of $10.57 million in the quarter ended June 30, 2026, widening 280% year over year.
• Operating loss widened 311% to $11.7 million as operating expenses more than doubled to $12.2 million, led by R&D up 342% to $7.4 million.
• Revenue was $500,000, swinging from no revenue a year earlier on a milestone under the Newsoara co-development agreement.
• Cash, cash equivalents and restricted cash totaled $125.2 million at June 30, 2026; management sees funding through key Phase 2 readouts in 2027-2028.
• FDA cleared the IND for the Phase 2 ASCENTRA-UC trial in June; first patient enrollment is expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001357459-26-000016), on August 10, 2026, and is solely responsible for the information contained therein.